Deeply rooted in the industry, we believe in joining forces to create empowerment and pursue win-win collaboration. We extend our sincere gratitude to FOFWEEKLY for their attention and recognition of TTM Capital.

Since the launch of its first fund in March 2022, TTM Capital has delivered outstanding investment returns. Notably, its flagship investment, XinThera, was acquired by a leading international pharmaceutical company just one year after investment, generating a nearly 10-fold return. The fund’s overall IRR exceeds 100%, and its DPI has reached nearly 40%.

Beyond performance, TTM Capital is guided by the vision of building robust soft power and adheres to the investment philosophy of “comprehensive linkage, multi-disciplinary sourcing, and strategic alliance.” The firm remains committed to in-depth collaboration with ecosystem partners. At this critical juncture—where policy tailwinds and technological breakthroughs are driving structural recovery across the industry—TTM Capital continues to enhance full-cycle support for its portfolio companies. This includes multi-dimensional assistance such as R&D resource integration, global expansion support, and commercialization strategy, effectively accelerating value realization for invested enterprises.

Moving forward, TTM Capital will further deepen cooperation within its ecosystem, strengthen its core competitive advantages through solid soft power, and contribute to innovation and sustainable development in the healthcare industry, injecting lasting momentum into the sector.

About FOFWEEKLY

FOFWEEKLY is a professional service platform for institutional investors in the private equity industry. Relying on in-depth content, targeted communities, and professional services, it promotes efficiency improvement for institutional investors, empowers the sustainable development of the private equity industry, and supports the global development of outstanding investment institutions.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.